1.Increase of red blood cell's mean corpuscular volume in the elderly normal population of Korea.
Soo Jung JE ; Cheolwon SUH ; Hyun Sook CHI
Korean Journal of Hematology 1992;27(2):227-231
No abstract available.
Aged*
;
Erythrocyte Indices*
;
Humans
;
Korea*
2.Non-gastric Marginal Zone B-cell Lymphoma in Korea: Clinical Features, Treatment, and Prognostic Factors.
The Korean Journal of Internal Medicine 2010;25(3):227-236
Marginal zone B-cell lymphoma (MZL) is the second most common subtype of non-Hodgkin's lymphoma in Korea (17.3%). Mucosa-associated lymphoid tissue (MALT) can develop in almost any organ as a result of exposure to a persistent stimulus, such as chronic infection or certain autoimmune processes. Under conditions of prolonged lymphoid proliferation, a malignant clone may emerge, which is followed by the development of a MALT lymphoma. Whereas MALT lymphoma of the stomach is the most common and the most extensively studied, we focus on non-gastric MZL studies conducted in Korea that highlight the most recent advances with respect to MZL definition, etiology, clinical characteristics, natural history, treatment approaches, outcomes, and prognostic factors. Moreover, we discuss current organ-specific considerations and controversies, and identify areas for future research.
Humans
;
Korea
;
Lymphoma, B-Cell, Marginal Zone/*diagnosis/*therapy
;
Neoplasm Staging
;
Organ Specificity
;
Prognosis
;
Splenic Neoplasms/diagnosis/therapy
3.The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective.
Cheolwon SUH ; Byeong Bae PARK ; Won Seog KIM
Blood Research 2017;52(1):3-6
No abstract available.
Lymphoma*
4.Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor.
Changhoon YOO ; Dok Hyun YOON ; Cheolwon SUH
Blood Research 2014;49(3):148-153
Beta-2 microglobulin is synthesized in all nucleated cells and forms the light chain subunit of the major histocompatibility complex class I antigen. Despite its potential role as a convenient and non-invasive prognostic indicator in malignant lymphomas, the influence of serum beta2 microglobulin is currently underestimated, and therapeutic decision making is rarely affected by this marker. Recent studies that included relatively large numbers of patients with specific histologic subtypes showed that serum beta2 microglobulin is a potent prognostic marker in malignant lymphomas. In follicular lymphoma, this effort led to the incorporation of serum beta2 microglobulin as an indicator in a new prognostic model. In this review, we summarize the current evidence supporting the role of serum beta2 microglobulin as a prognostic factor in patients with malignant lymphoma and discuss perspectives for future investigations.
Decision Making
;
Humans
;
Lymphoma*
;
Lymphoma, Follicular
;
Major Histocompatibility Complex
5.Relevance of prognostic index with β2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era.
Jihoon KANG ; Shinkyo YOON ; Cheolwon SUH
Blood Research 2017;52(4):276-284
BACKGROUND: The International Prognostic Index (IPI) has been a useful tool for predicting the prognosis of aggressive non-Hodgkin lymphoma in the last 20 years. Herein, we aimed to develop a new prognostic model for diffuse large B-cell lymphoma (DLBCL) in the rituximab era. METHODS: Between March 2004 and June 2012, patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy regimen were identified in the database of the Asan Medical Center (AMC) Lymphoma Registry. The primary and secondary endpoints were a new prognostic index for DLBCL and validation of the National Comprehensive Cancer Network-International Prognostic Index in our cohort, respectively. RESULTS: The AMC cohort comprised 621 patients. The median follow-up duration was 43.3 months (range, 6.2–122.5 mo). Univariate analysis revealed that age (≤60 vs. >60 yr), lactate dehydrogenase (LDH; within normal vs. increased), Eastern Cooperative Oncology Group performance status (ECOG PS; 0 or 1 vs. ≥2), advanced stage (Ann Arbor stage I/II vs. III/IV), extra-nodal involvement (≤1 vs. >1), B symptoms (no vs. yes), and beta-2 microglobulin (β2MG, ≤2.5 vs. >2.5) can be used to predict overall survival (OS). In multivariate analysis, only age, LDH, ECOG performance status, and β2MG were significantly associated with OS, and we developed a new prognostic model with these 4 factors. The new prognostic model showed better discriminative power compared with the classic IPI. CONCLUSION: Our new prognostic index model for DLBCL in the rituximab era has good discriminative power and is convenient to use.
B-Lymphocytes*
;
Chungcheongnam-do
;
Cohort Studies
;
Cyclophosphamide
;
Doxorubicin
;
Drug Therapy
;
Follow-Up Studies
;
Humans
;
L-Lactate Dehydrogenase
;
Lymphoma
;
Lymphoma, B-Cell*
;
Lymphoma, Non-Hodgkin
;
Multivariate Analysis
;
Prednisolone
;
Prognosis
;
Rituximab*
;
Vincristine
6.Clinical features and survival outcomes of patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single-center experience.
Jihoon KANG ; Jung Yong HONG ; Cheolwon SUH
Blood Research 2018;53(3):189-197
BACKGROUND: The incidence of lymphoplasmacytic lymphoma (LPL) is lower in Asian than in Western populations. Few studies have described the clinical features and treatment outcomes of patients with LPL, including non-IgM LPL, in East Asia. METHODS: We retrospectively analyzed patients diagnosed with LPL at Asan Medical Center between January 2001 and March 2016. We evaluated the clinical features and survival outcomes of patients with LPL and non-IgM LPL and compared these data with those of patients with LPL/Waldenström's macroglobulinemia (WM). RESULTS: The median age at diagnosis of patients with LPL was 61.5 years (range, 34–77 yr); most patients were male (91%). Approximately three-quarters of the 22 patients with LPL were in the low or intermediate risk groups according to the International Prognostic Scoring System for Waldenström's Macroglobulinemia classification. The median follow-up duration was 75 months [95% confidence interval (CI), 48–102 mo], and the median overall survival (OS) was 81 months (95% CI, 0–167 mo). The number of patients in the non-IgM LPL group who exhibited extramedullary involvement was higher than in the LPL/WM group. OS of the LPL/WM group was improved compared with that of the non-IgM LPL group [median not reached vs. 10.0 mo (95% CI, 0–36.7); P=0.05]. CONCLUSION: We present a single-center experience of 22 patients with LPL, including a non-IgM cohort, in Korea. The treatment of non-IgM LPL was heterogeneous, and patients with non-IgM LPL showed a higher 5-year mortality rate and more adverse prognostic factors than those with LPL/WM.
Asian Continental Ancestry Group
;
Chungcheongnam-do
;
Classification
;
Cohort Studies
;
Diagnosis
;
Far East
;
Follow-Up Studies
;
Humans
;
Incidence
;
Korea*
;
Lymphoma*
;
Male
;
Mortality
;
Retrospective Studies
;
Waldenstrom Macroglobulinemia
7.Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma.
Hee Sang HWANG ; Dok Hyun YOON ; Cheolwon SUH ; Chan Sik PARK ; Jooryung HUH
Blood Research 2013;48(4):266-273
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous clinicopathological entity, and its molecular classification into germinal center B cell-like (GCB) and activated B cell-like (ABC) subtypes using gene expression profile analysis has been shown to have prognostic significance. Recent attempts have been made to find an association between immunohistochemical findings and molecular subgroup, although the clinical utility of immunohistochemical classification remains uncertain. METHODS: The clinicopathological features and follow-up data of 68 cases of surgically resected gastrointestinal DLBCL were analyzed. Using the immunohistochemical findings on tissue microarray, the cases were categorized into GCB and non-GCB subtypes according to the algorithms proposed by Hans, Muris, Choi, and Tally. RESULTS: The median patient age was 56 years (range, 26-77 years). Of the 68 cases included, 39.7% (27/68) involved the stomach, and 60.3% (41/68) involved the intestines. The GCB and non-GCB groups sorted according to Hans, Choi, and Tally algorithms, but not the Muris algorithm, were closely concordant (Hans vs. Choi, kappa=0.775, P<0.001; Hans vs. Tally, kappa=0.724, P<0.001; Choi vs. Tally, kappa=0.528, P<0.001). However, there was no prognostic difference between the GCB and non-GCB subtypes, regardless of the algorithm used. On univariate survival analyses, international prognostic index risk group and depth of tumor invasion both had prognostic significance. CONCLUSION: The Hans, Choi, and Tally algorithms might represent identical DLBCL subgroups, but this grouping did not correlate with prognosis. Further studies may delineate the association between immunohistochemical subgroups and prognosis.
B-Lymphocytes*
;
Classification
;
Follow-Up Studies
;
Gastrointestinal Tract
;
Germinal Center
;
Humans
;
Immunohistochemistry
;
Intestines
;
Lymphoma, B-Cell*
;
Prognosis
;
Stomach
;
Transcriptome
8.Refractoriness to platelet transfusion after single-donor consecutive platelet transfusions and its relationship to platelet antibodies.
Munho LEE ; Byoung Kook KIM ; Seonyang PARK ; Cheolwon SUH ; Myoung Hee PARK ; Myong Joon CHO
Journal of Korean Medical Science 1988;3(4):143-149
In thirty patients with acute leukemia and severe aplastic anemia receiving random single donor platelet transfusions, the development of refractoriness by consecutive platelet transfusions with cytapheresis and its relationship to the appearance of anti-platelet antibodies were investigated. The median number of platelet transfusions inducing refractoriness was 13 times, and 20% of the patients remained unrefractory despite of the repeated multiple platelet transfusions up to 20 to 25 times. The results of anti-platelet antibody tasts by the enzyme-linked immunosorbent assay(ELISA) and immunofluorescent techniques(IFT) showed no statistically significant relationship with the refractoriness (p greater than 0.1). Although there was significant correlation between the results of ELISA and IFT, both tests were insufficient to find out refractoriness even with the use of pooled platelets from multiple donors as target cells. This study shows that 13 single donor platelet transfusions result in refractoriness, that both ELISA and IFT are insufficient to detect refractoriness despite of their significant correlation, and that other methods than these are needed in order to detect alloimmunization.
Adolescent
;
Adult
;
Aged
;
Anemia, Aplastic/therapy
;
Anemia, Refractory/*etiology
;
Antibodies/metabolism
;
*Blood Platelets/immunology
;
*Blood Transfusion
;
Female
;
Humans
;
Leukemia/therapy
;
Male
;
Middle Aged
9.Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party.
Cheolwon SUH ; Won Seog KIM ; Jin Seok KIM ; Byeong Bae PARK
Blood Research 2013;48(3):171-177
The Consortium for Improving Survival of Lymphoma (CISL) in Korean Society of Hematology Lymphoma Working Party had first meeting in February, 2006 with 10 institutions and 12 members. Now CISL comprised of 64 centers. CISL has concentrated research activity on lymphomas which are relatively frequent in Korea and has tried to give favors for the Korean lymphoma patients. CISL has conducted more than 30 retrospective studies to evaluate Korean peculiar lymphoma subtypes. More than 30 prospective trials have been being performed for diffuse large B-cell lymphoma, marginal zone lymphoma, extra-nodal NK/T-cell lymphoma, and so on. The first prospective trial for advanced marginal zone lymphoma has led to use Rituximab containing chemotherapy with the re-imbursement of health insurance in Korea. The multi-center trials of the CISL with new therapeutic modalities will improve further the survival of lymphoma patients not only quantitatively but also qualitatively.
Antibodies, Monoclonal, Murine-Derived
;
Hematology
;
Humans
;
Insurance, Health
;
Korea
;
Lymphoma
;
Lymphoma, B-Cell
;
Rituximab
10.Intestinal Diffuse Large B-Cell Lymphoma: An Evaluation of Different Staging Systems.
Hee Sang HWANG ; Dok Hyun YOON ; Cheolwon SUH ; Chan Sik PARK ; Jooryung HUH
Journal of Korean Medical Science 2014;29(1):53-60
The gastrointestinal tract is the most common primary extranodal site for diffuse large B-cell lymphoma (DLBCL). However, there is no consensus on the most appropriate staging system for intestinal DLBCL. We evaluated the utility of the modified Ann Arbor system, the Lugano system, and the Paris staging system (a modification of the Tumor, Node, Metastases [TNM] staging for epithelial tumors) in 66 cases of resected intestinal DLBCL. The cases were treated with surgery, plus either cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy alone (n=26) or with the addition of rituximab immunotherapy (n=40). Median follow-up time was 40.4 months (range, 2.1-171.6 months). Fifty-six patients (84.8%) achieved complete remission. The overall 5-yr survival rate was 86.4% (57/66). Of the stage categories defined for each staging system, only the T stage of the Paris classification showed prognostic significance for overall survival by univariate analysis. However, none of the stage parameters was significantly correlated with patient survival on multivariate analysis. In conclusion, the results suggest that the T stage of the Paris classification system may be a prognostic indicator in intestinal DLBCL. The results also imply that in surgically resected intestinal DLBCL, the addition of rituximab to the CHOP regimen does not confer significant survival advantage.
Adolescent
;
Adult
;
Aged
;
Antibodies, Monoclonal, Murine-Derived/therapeutic use
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
;
Cyclophosphamide/therapeutic use
;
Doxorubicin/therapeutic use
;
Female
;
Humans
;
Immunologic Factors/therapeutic use
;
Intestinal Neoplasms/*classification/drug therapy/mortality/surgery
;
Lymphoma, Large B-Cell, Diffuse/*classification/drug therapy/mortality/surgery
;
Male
;
Middle Aged
;
Neoplasm Staging/*methods
;
Prednisone/therapeutic use
;
Retrospective Studies
;
Survival
;
Survival Rate
;
Treatment Outcome
;
Vincristine/therapeutic use
;
Young Adult